Medical Condition News

RSS

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, today announced the initiation of a feasibility clinical trial designed to evaluate the safety and efficacy of a combined surgical and catheter procedure, the convergent procedure, for the treatment of symptomatic paroxysmal atrial fibrillation (AF). This prospective, feasibility study will enroll patients at study sites across the United States.

2 Dec 2009

Development of novel virus can lead to new therapeutic strategy to combat cancer

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels.

2 Dec 2009

$Careful diagnosis can help avoid long-term disabilities associated with uncommon fractures$

Careful diagnosis can help avoid long-term disabilities associated with uncommon fractures

Located in areas of the foot that can be hard to visualize with X-rays and other imaging techniques, injuries to the ankle area of the foot are the most frequently misdiagnosed of all foot fractures. Delayed diagnosis can have serious consequences, sometimes leading to permanent disability.

2 Dec 2009

Roche announces results of phase III taspoglutide study in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche.

2 Dec 2009

Bioactive sponge to eliminate normally fatal tumors

InCytu Incorporated, a therapeutic device engineering company, announced the details of its Cellarium™ Cancer Vaccine program. Cellarium™ is a small bioactive sponge which regulates dendritic cells and T-cells to eliminate normally fatal tumors in a preclinical model of late stage melanoma. The details of such a promising new vaccine were published for the first time in Science’s Translational Medicine Journal.

2 Dec 2009

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

Harvest Technologies Corp. announced today results from the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical Center in Chennai, India using the company's BMAC System to treat patients with non-reconstructable Critical Limb Ischemia (CLI). Sri Ramachandra Medical Center is a Harvard Medical international-associated institution based in Chennai, India and one of the largest private healthcare facilities in South Asia.

2 Dec 2009

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

ImThera Medical, Inc. today announced that two patients have been surgically implanted with ImThera’s aura6000™ neurostimulation device for treating tongue-based Obstructive Sleep Apnea (OSA). Patients are being enrolled in ImThera’s pilot clinical investigation in Belgium with the first results expected to be published in the first half of 2010.

2 Dec 2009

Cancer Prevention Research Conference highlights new research on cancer

The American Association for Cancer Research Frontiers in Cancer Prevention Research Conference will focus on the latest biological, medical and social research behind cancer prevention.

2 Dec 2009

ASH Annual Meeting to showcase latest research and treatments for blood disorders

The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood disorders.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

Researchers develop new application for improved detection of breast cancer cells

Single-walled nanotubes—cylinders of carbon about a nanometer in diameter—have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for fuel cells. Thanks to a new development by researchers at the National Institute of Standards and Technology (NIST) and five partners, you can add one more application to the list: detection and destruction of an aggressive form of breast cancer.

2 Dec 2009

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

2 Dec 2009

J&JPRD submits an NDA for tapentadol ER tablets

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older.

2 Dec 2009

New preventive screening packages for heart disease

HealthYes!®, a leading mobile medical screening provider, is offering several new preventive screenings directly focused on heart disease. The new tests include: a six-lead electrocardiogram (EKG), cholesterol finger-stick, and 10-year Framingham Cardiac Risk Score as well as diabetes and liver function testing.

2 Dec 2009

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University of Texas M. D. Anderson Cancer Center.

2 Dec 2009

Surgeons remove rectal mass using innovative surgical approach

Performing surgical operations without leaving scars has ceased to be a chimera and has become a reality. This is demonstrated by the recent surgical advances made using NOTES (Natural Orifice Transluminal Endoscopy Surgery), an innovative surgical approach that allows surgical access using the body's natural orifices.

2 Dec 2009

Overall use of blood-thinning agents not improving despite more options

Since 1999, stroke survivors have been advised to use aspirin, prescription antiplatelet agents, or prescription anticoagulants to help avoid another stroke. Many large surveys of the U.S. population have reported the use of aspirin for secondary prevention, but commonly combine people with stroke and coronary artery disease, and only rarely report the use of antithrombotic agents other than aspirin.

2 Dec 2009

Schools need to sell healthy foods to cut junk food intake

It seems like a no-brainer, and it is: Take the junk food out of school vending machines and cafeterias, and kids will eat less junk food, according to a new study that took place in Connecticut.

2 Dec 2009

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

Cancer researchers at the University of Oklahoma Health Sciences Center have found a way to turn ineffective new cancer drugs into cancer-fighters. By using their patented chemical compound, SHetA2, researchers tricked cancer cells into responding to new treatments and undergoing cell suicide.

2 Dec 2009

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

2 Dec 2009

Medical Condition News

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

Development of novel virus can lead to new therapeutic strategy to combat cancer

Careful diagnosis can help avoid long-term disabilities associated with uncommon fractures

Roche announces results of phase III taspoglutide study in diabetes patients

Bioactive sponge to eliminate normally fatal tumors

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

Cancer Prevention Research Conference highlights new research on cancer

ASH Annual Meeting to showcase latest research and treatments for blood disorders

New approach to identify molecules that prevent immune cells from attacking body

Researchers develop new application for improved detection of breast cancer cells

Boehringer Ingelheim to announce positive results from its RE-COVER study

J&JPRD submits an NDA for tapentadol ER tablets

New preventive screening packages for heart disease

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Surgeons remove rectal mass using innovative surgical approach

Overall use of blood-thinning agents not improving despite more options

Schools need to sell healthy foods to cut junk food intake

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News